Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02865499 · ClinicalTrials.gov registry record · Phase 2

Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)

A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 2
Development phase
8
Enrollment target

NCT02865499 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02865499, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 2
Development phase
8 participants
Enrollment target

Study Summary

This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans. It is a pilot study to: i) better estimate power for a larger trial, ii) establish the safety and potential beneficial effects of acarbose in non-diabetic elderly humans, and iii) determine whether the effects of acarbose on the microbiome likely play a role in its enhancement of longevity and/or healthy aging. These are essential initial steps for translating acarbose into an anti-aging human therapy.

Interventions

  • DRUG acarbose

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2016-06
Est. Completion 2017-10
Phase Phase 2

What the Registry Record Tells You About NCT02865499

The ClinicalTrials.gov registry entry for NCT02865499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which acarbose is the first listed.

NCT02865499 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02865499 about?

NCT02865499 is a clinical study titled "Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)". This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans. It is a pilot study to: i) better estimate power for a larger trial, ii) establish the safety and potential beneficial effects of acarb...

What is the current status of trial NCT02865499?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-06. Estimated completion is 2017-10.

What interventions are being tested in trial NCT02865499?

The interventions under investigation include: acarbose (DRUG).

Who is sponsoring clinical trial NCT02865499?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.